Trinity Biotech plc

NasdaqGS:TRIB Stock Report

Market Cap: US$10.6m

Trinity Biotech Future Growth

Future criteria checks 1/6

Trinity Biotech is forecast to grow earnings and revenue by 33.2% and 11.8% per annum respectively while EPS is expected to grow by 55.6% per annum.

Key information

33.2%

Earnings growth rate

55.6%

EPS growth rate

Medical Equipment earnings growth17.1%
Revenue growth rate11.8%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Sep 25
Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Aug 07
A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18
Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Sep 12
A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Aug 08
Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Jun 09
Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

Apr 23
Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23
This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01
Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01
At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Earnings and Revenue Growth Forecasts

NasdaqGS:TRIB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202678-8361
12/31/202569-15-11-81
12/31/202462-20-10-91
9/30/202459-20-16-7N/A
6/30/202459-22-14-8N/A
3/31/202457-34-15-12N/A
12/31/202357-37-14-12N/A
9/30/202371-39-13-10N/A
6/30/202354-46-8-5N/A
3/31/202374-34-7-2N/A
12/31/202263-44-7-1N/A
9/30/202276-32-62N/A
6/30/202279-22-53N/A
3/31/202286-13-26N/A
12/31/202181-2513N/A
9/30/2021106-81120N/A
6/30/2021116-21827N/A
3/31/2021106-21929N/A
12/31/2020102-61424N/A
9/30/202091-20-17N/A
6/30/202083-27-65N/A
3/31/202090-31-210N/A
12/31/201990-29-65N/A
9/30/201994-30-411N/A
6/30/201993-29-79N/A
3/31/201995-23-79N/A
12/31/201897-23-107N/A
9/30/201897-39-107N/A
6/30/201899-40N/A8N/A
3/31/201899-40N/A10N/A
12/31/201799-39N/A9N/A
9/30/201798-36N/A8N/A
6/30/201799-37N/A10N/A
3/31/2017100-36N/A8N/A
12/31/2016100-39N/A10N/A
9/30/20161013N/A17N/A
6/30/201610116N/A14N/A
3/31/20169816N/A13N/A
12/31/201510022N/A13N/A
9/30/201510123N/A15N/A
6/30/201510315N/A17N/A
3/31/201510517N/A16N/A
12/31/201410515N/A16N/A
9/30/201410318N/A8N/A
6/30/201410010N/A6N/A
3/31/20149510N/A8N/A
12/31/20139110N/A9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRIB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRIB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRIB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRIB's revenue (11.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: TRIB's revenue (11.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TRIB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y